LDL-C and ApoB measurements do not adequately capture risk of atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis (AVS). This is the conclusion from an analysis of data from 70,189 individuals in the Copenhagen General Population Study, 7,127 of whom developed ASCVD and 1,516 developed AVS during a median 10.8 years of follow up.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
